Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases

Tijsen, Anke J.; Pinto, Yigal M.; Creemers, Esther E.

doi:10.1152/ajpheart.00191.2012

Cited by 182 publications

(150 citation statements)

References 58 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

“…3,67) On the other hand, miRNAs are reportedly present in the circulation and are found to be stable in plasma. 68) Since their identification in the circulation, miRNAs have attracted much interest as novel biomarkers of cardiovascular diseases.…”

Section: Circulating Micrornasmentioning

confidence: 99%

“…1,2) Although a number of biomarkers have been developed, the ideal biomarkers should meet certain criteria: 1) non-invasive sample collection, 2) a high degree of sensitivity and specificity, 3) able to detect the disease at an early stage, 4) sensitivity high enough to reflect relevant changes in disease conditions, 5) a long halflife within the sample, 6) rapid measurement system responding to clinical needs, and 7) low cost. 3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers in Heart Failure

Takeishi

2014

Int. Heart J.

View full text Add to dashboard Cite

SummaryAppropriate use of biomarkers is clinically important for identifying heart failure in its early stage, optimizing risk stratification, and managing patients. This article describes established and traditional biomarkers as well as novel biomarkers reflective of myocardial stress, myocardial damage, extracellular matrix, oxidative stress, inflammation, renal function, micro RNAs, and heart failure with preserved left ventricular ejection fraction. This review focuses on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. (Int Heart J 2014; 55: 474-481) Key words: BNP, NT-proBNP, ST2, Troponin, H-FABP, Galectin-3, Cystatin C, Pentraxin 3 C ardiovascular diseases are the predominant cause of death in developed countries. Among the afflicted, patients with heart failure are increasing, and this complex syndrome is becoming a public health problem, especially with the aging of populations. To establish diagnostic, therapeutic, and prognostic strategies, the identification of reliable biomarkers for heart failure is necessary.1,2) Although a number of biomarkers have been developed, the ideal biomarkers should meet certain criteria: 1) non-invasive sample collection, 2) a high degree of sensitivity and specificity, 3) able to detect the disease at an early stage, 4) sensitivity high enough to reflect relevant changes in disease conditions, 5) a long halflife within the sample, 6) rapid measurement system responding to clinical needs, and 7) low cost. 3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. Myocardial Stress MarkersB-type natriuretic peptide: B-type natriuretic peptide (BNP) is a well-established biomarker, extensively used for the diagnosis and prognosis of patients with heart failure. BNP is a cardiac hormone, identified as the second compound of the natriuretic peptide family and secreted predominantly from the ventricle in response to mechanical overload. 5) In the failing heart, increased wall stress and neurohormonal activation facilitate BNP secretion chiefly from ventricular myocytes. BNP promotes diuresis, vasodilatation, and attenuation of renin and aldosterone secretion. Tsutamoto, et al initially measured plasma levels of BNP in 85 patients with chronic heart failure and a left ventricular ejection fraction (LVEF) of less than 0.45. 6)The plasma levels of BNP increased in proportion to the severity of heart failure. Plasma levels of BNP were 5-fold higher in non-survivors than in survivors. Among clinical and hemodynamic parameters, Cox proportional hazard analysis revealed that only plasma BNP (P < 0.0001) and pulmonary capillary wedge pressure (P = 0.003) were significant independent predictors of mortality in patients with heart failure. Plasma levels of BNP provided prognostic information independent of other variables previously associated with a poor prognosis. To date, a number of studies have r...

show abstract

“…3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Section: Circulating Micrornasmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in Heart Failure

Takeishi

2014

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…More than 200 miRNAs have been detected in the heart and distinctive miRNA profiles have been identified between myocardial infarction (MI), heart failure, myocarditis, Type 2 diabetes, atherosclerotic disease and hypertension [29,30]. miRNAs that are released from necrotic cardiomyocytes after MI have been proposed as new early biomarkers in diagnosing acute MI [31].…”

Section: Mirna In Cardiovascular Diseasesmentioning

confidence: 99%

MicroRNAs as Potential Prognosticators of Neurological Outcome in Out-Of-Hospital Cardiac Arrest Patients

et al. 2017

View full text Add to dashboard Cite

Out-of-hospital cardiac arrest survival rates have increased due to advancement in resuscitative measures, yet approximately 90% of survivors ultimately die or have severe neurologic dysfunction caused by ischemic injury. Currently, there are few early prognostic indicators of which patients have possibility of meaningful recovery. This leads to uncertainty for families and clinicians, as well as aggressive, invasive and expensive treatments despite medical futility. Several biomarkers investigated in traumatic brain injury have shown prognostication potential in ischemic brain injury. miRNAs, small noncoding RNAs responsible for gene regulation, have been studied in cardiovascular diseases, and have shown prognostication potential due to tissue specificity and stability in circulation. This review discusses available evidence on miRNAs prognosticating neurological outcomes after out-of-hospital cardiac arrest.

show abstract

“…Recent studies focused their attention to miRNAs as possible circulating and tissue biomarkers of several diseases [9,10], comprising cardiac-related maladies [11,12]. Indeed, miRNAs play a key role in many biological processes, including cardiac functions like conductance of electrical signals, heart muscle contraction, growth, and pathogenesis of cardiovascular diseases [13].…”

Section: Micrornasmentioning

confidence: 99%

Early diagnosis of doxorubicin-induced cardiotoxicity:The miRNA way

D’Alessandra¹

2017

Cardiovasc Disord Med

View full text Add to dashboard Cite

This short commentary focuses on the use of circulating microRNAs as biomarkers of doxorubicin-induced cardiotoxicity in cancer patients undergoing chemotherapy. Cancer is one of the leading causes of death worldwide and is usually treated following different approaches; among these, anticancer drugs have a very important role. One of the most effective molecules is Doxorubicin (DOX), a two-edged sword which combines several beneficial effects with the lack of cancer-cell specificity. DOX toxicity is known to be able to compromise the clinical effectiveness of chemotherapy, strongly impacting patients' quality of life and survival, even years after its administration. It is associated with progressive disruption of cardiac function, and can progressively develop into heart failure. Despite the availability of different cardiac biomarkers (i.e., troponins, B-type natriuretic peptide) presenting several positive features like high sensitivity, cardiac specificity and low invasivity, reliable and timely risk assessment in long-term cancer survivors is still difficult to achieve. Indeed, cardiotoxicity is usually detected late when heart impairment has already occurred and is quite evident. Evaluation of left ventricle ejection fraction (LVEF) by imaging techniques is still the only reliable and accepted diagnostic tool but does not allow early prevention. In the past years, several efforts were made to identify new biomarkers for early assessment and diagnosis of cardiovascular diseases. Lately, a new class of circulating molecules, microRNAs (miRNAs), emerged, and many groups evidenced their possible exploitation as biomarkers due to their stability in several body fluids and to the possibility to detect them even at small concentrations. Despite the clinical relevancy, only a handful of studies have focused their attention on investigating the role of microRNAs in DOX-induced cardiotoxicity, mostly relying on the use animal models. Very recently, a few groups started to examine whether circulating miRNAs could represent new and reliable early cardiotoxicity biomarkers.

show abstract

Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases

Abstract: Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases.

Cited by 182 publications

References 58 publications

Biomarkers in Heart Failure

Biomarkers in Heart Failure

MicroRNAs as Potential Prognosticators of Neurological Outcome in Out-Of-Hospital Cardiac Arrest Patients

Early diagnosis of doxorubicin-induced cardiotoxicity:The miRNA way

Contact Info

Product

Resources

About